%0 Journal Article
%A Solomonidou, Nantia
%A Germanou, Daphnie
%A Strouthos, Iosif
%A Karagiannis, Efstratios
%A Farolfi, Andrea
%A Koerber, Stefan A
%A Debus, Jürgen
%A Peeken, Jan C
%A Vogel, Marco E
%A Vrachimis, Alexis
%A Spohn, Simon K B
%A Shelan, Mohamed
%A Aebersold, Daniel
%A Grosu, Anca-Ligia
%A Ceci, Francesco
%A Kroeze, Stephanie G C
%A Guckenberger, Matthias
%A Fanti, Stefano
%A Belka, Claus
%A Hruby, George
%A Scharl, S.
%A Wiegel, Thomas
%A Bartenstein, Peter
%A Henkenberens, Christoph
%A Emmett, Louise
%A Schmidt-Hegemann, Nina Sophie
%A Ferentinos, Konstantinos
%A Zamboglou, Constantinos
%T PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA </td><td width="150">
%T lt; 0.2 ng/ml.
%J European journal of nuclear medicine and molecular imaging
%V 50
%N 8
%@ 1619-7070
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2023-00497
%P 2529-2536
%D 2023
%Z 2023 Jul;50(8):2529-2536
%X The purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2 ng/ml.The study included patients from a pooled cohort (n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2 ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2 ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed.The final cohort consisted of 273 patients; 78/273 (28.6
%K PSMA-PET (Other)
%K Prostate cancer (Other)
%K Prostate-specific antigen (Other)
%K Salvage radiotherapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36905411
%R 10.1007/s00259-023-06185-5
%U https://inrepo02.dkfz.de/record/274211